All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How to treat cytopenic patients with MPN
Featured
During the MPN Hub steering committee roundtable discussion we were pleased to invite Dr Haifa Kathrin Al-Ali University Hospital Halle (Saale), Halle, Germany to give a presentation on how to treat cytopenic patients with MPN.
How to treat cytopenic patients with MPN
Dr Al-Ali opens the presentation by outlining the differences between cytopenic and myeloproliferative MF before giving an overview of the various treatment options available to cytopenic patients and their role in the clinical landscape. She concludes by highlighting investigational agents currently in clinical trials.
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox